Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Identifying a clinically meaningful change in cognitive test score is essential when using cognition as an outcome in clinical trials. This is especially relevant because clinical trials increasingly feature novel composites of cognitive tests. Our primary objective was to establish minimal clinically important differences (MCIDs) for commonly used cognitive tests, using anchor-based and distribution-based methods, and our secondary objective was to investigate a composite cognitive measure that best predicts a minimal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB). METHODS: From the Swedish BioFINDER cohort study, we consecutively included cognitively unimpaired (CU) individuals with and without subjective or mild cognitive impairment (MCI). We calculated MCIDs associated with a change of ≥0.5 or ≥1.0 on CDR-SB for Mini-Mental State Examination (MMSE), ADAS-Cog delayed recall 10-word list, Stroop, Letter S Fluency, Animal Fluency, Symbol Digit Modalities Test (SDMT) and Trailmaking Test (TMT) A and B, and triangulated MCIDs for clinical use for CU, MCI, and amyloid-positive CU participants. For investigating cognitive measures that best predict a change in CDR-SB of ≥0.5 or ≥1.0 point, we conducted receiver operating characteristic analyses. RESULTS: Our study included 451 cognitively unimpaired individuals, 90 with subjective cognitive decline and 361 without symptoms of cognitive decline (pooled mean follow-up time 32.4 months, SD 26.8, range 12-96 months), and 292 people with MCI (pooled mean follow-up time 19.2 months, SD 19.0, range 12-72 months). We identified potential triangulated MCIDs (cognitively unimpaired; MCI) on a range of cognitive test outcomes: MMSE -1.5, -1.7; ADAS delayed recall 1.4, 1.1; Stroop 5.5, 9.3; Animal Fluency: -2.8, -2.9; Letter S Fluency -2.9, -1.8; SDMT: -3.5, -3.8; TMT A 11.7, 13.0; and TMT B 24.4, 20.1. For amyloid-positive CU, we found the best predicting composite cognitive measure included gender and changes in ADAS delayed recall, MMSE, SDMT, and TMT B. This produced an AUC of 0.87 (95% CI 0.79-0.94, sensitivity 75%, specificity 88%). DISCUSSION: Our MCIDs may be applied in clinical practice or clinical trials for identifying whether a clinically relevant change has occurred. The composite measure can be useful as a clinically relevant cognitive test outcome in preclinical AD trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Changes in Trails B by 20 s was suggested to be a clinically meaningful change in a cohort of older adults with MCI.50”
From A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Multimodel Inference: Understanding AIC and BIC in Model Selection
Burnham, K. P., & Anderson, D. R. (2004) · Sociological Methods & Research · doi:10.1177/0049124104268644 · Cited by 11,648
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056 · cited 1×
“5 = questionable, 1 = mild, 2 = moderate, and 3 = severe) in domains (box scores) of memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.(9,10) Participants in this study were rated on the CDR by a thorough review of patient records where dementia experts assessed…”
Effect size estimates: Current use, calculations, and interpretation.
Fritz, C. O., Morris, P. E., & Richler, J. J. (2012) · Journal of Experimental Psychology: General · doi:10.1037/a0024338 · Cited by 5,199
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Determining Amyloid Positivity The procedure and analysis of CSF followed the Alzheimer Association Flowchart for CSF biomarkers.(15,16) We used the ratio for Aβ42/40 that we establish acquire through CSF analysis.”
mixtools: An R Package for Analyzing Finite Mixture Models
Benaglia, T., Chauveau, D., Hunter, D. R., & Young, D. (2009) · Journal of Statistical Software · doi:10.18637/jss.v032.i06 · Cited by 1,271
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760
Cited by
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Warmenhoven, N., Salvadó, G., Janelidze, S., Mattsson, N., Bali, D., Dolado, A. O., Kolb, H. C., Triana‐Baltzer, G., Barthélemy, N. R., Schindler, S. E., et al. (2024) · Brain · doi:10.1093/brain/awae346 · Cited by 166
Self-citationMinimal clinically important difference in Alzheimer's disease: Rapid review
Muir, R. T., Hill, M. D., Black, S. E., & Smith, E. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13770 · Cited by 124
Millar, C. L., Iloputaife, I., Baldyga, K., Norling, A. M., Boulougoura, A., Vichos, T., Tchkonia, T., Deisinger, A., Pirtskhalava, T., Kirkland, J. L., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105612 · Cited by 88
“50 Furthermore, those with lower cognitive scores at baseline and thus with the most potential to improve, had a signi fi cant increase of approximately 2 points in MoCA scores at fi nal follow-up compared to baseline.”
Minimal Clinically Important Differences of Spatiotemporal Gait Variables in Parkinson Disease
Baudendistel, S. T., Haussler, A. M., Rawson, K. S., & Earhart, G. M. (2023) · Gait & Posture · doi:10.1016/j.gaitpost.2023.11.016 · Cited by 52
Pagali, S. R., Kumar, R., LeMahieu, A., Basso, M. R., Boeve, B. F., Croarkin, P. E., Geske, J. R., Hassett, L. C., Huston, J., Kung, S., et al. (2024) · International Psychogeriatrics · doi:10.1017/s1041610224000085 · Cited by 57
Metadata
- Authors
- Borland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O., & Palmqvist, S.
- Affiliations
- Lund University (SE)
- Corresponding author
- Borland, Emma
- Venue
- Neurology
- Published
- 2022-09-13
- Volume
- 99
- Issue
- 11
- Pages
- e1142-e1153
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC9536741
- OpenAlex
- W4285495175
- Cited by
- 83
- References
- 44
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 21 · 2023: 14 · 2022: 1
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-01-23)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Lunds Universitet
- Knut och Alice Wallenbergs Stiftelse (2017‐0383)
- Vetenskapsrådet (2016-00906, FO2021-0293, 2018-, 2018-02052, 2017-00383)
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, 2020-0314)
- Skånes universitetssjukhus (2020-O000028)
- Marcus och Amalia Wallenbergs minnesfond (2015.0125)
- Parkinsonfonden (1280/20)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
- Keywords
- minimal clinically important difference, cognitive outcome measures, mild cognitive impairment, subjective cognitive decline, prodromal Alzheimer's disease, CDR-SB, Mini-Mental State Examination, Symbol Digit Modalities Test, Trail Making Test, Stroop task, cognitive decline prediction
- MeSH terms
- Alzheimer Disease, Cognition, Humans, Neuropsychological Tests, Cohort Studies, Cognitive Dysfunction, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. https://app.cochat.ai/papers/10.1212/wnl.0000000000200817
- The paper
- Borland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O., & Palmqvist, S. (2022). Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. Neurology. https://doi.org/10.1212/wnl.0000000000200817
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.